GlassScriptPhysician profile
Michael H Peters
NPI 1598726580
$12,507.08
in general payments reported to CMS, 2019-2025
43 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $981 · 2021: $1,889 · 2022: $1,855 · 2023: $2,891 · 2024: $1,620 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,769 · Travel and Lodging: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,768.53 |
| Travel and Lodging | $845.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,185.11 | 2019-2025 | |
| Abbott Laboratories | $1,863.00 | 2020-2025 | Aveir, Triclip, Cardiomems |
| Edwards Lifesciences Corporation | $1,356.10 | 2023-2025 | Pascal, Mitris Resilia Mitral Valve |
| Janssen Pharmaceuticals, INC | $1,115.82 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,045.11 | 2019-2025 | |
| Amgen INC. | $823.53 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $583.88 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $362.50 | 2021-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $339.02 | 2022-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.64 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $271.25 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $257.73 | 2019-2024 | |
| Bridgebio Pharma, INC. | $191.55 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.04 | 2019-2025 | Lifevest |
| Scpharmaceuticals INC. | $159.61 | 2024-2025 |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.